Skip to main content
NVDA+0.21%AAPL-0.23%GOOGL+0.30%MSFT-0.42%AMZN-0.29%TSM+0.17%SPCX-4.21%META+0.03%AVGO+0.73%TSLA-0.15%BRK-B+0.61%SKHY-3.19%LLY-1.36%MU+0.27%AMD+1.90%WMT-0.71%JPM-0.86%V+1.74%XOM+1.12%ASMLa-4.20%JNJ-5.73%MA+1.63%INTC+1.44%0700.HK-0.03%ABBV-2.40%1398.HK-1.41%CSCO-0.23%CVX+1.27%COST-0.50%ORCL+4.23%KO+0.36%BAC-1.14%DELL-0.72%LRCX-2.73%AMAT-6.69%PG-0.10%AP2d-8.45%CAT-3.33%UNH-0.20%3988.HK-1.16%1816.HK-25.11%0005.HK-1.09%HSBA.L+0.17%0857.HK+0.29%GE-0.33%PM-1.34%0939.HK-1.63%1288.HK-2.19%MS-1.78%NFLX-0.21%CADCHF+0.61%GBPCHF+0.52%AUDCHF+0.46%NZDCHF+0.45%GBPTRY+0.41%USDCAD-0.39%EURCAD-0.35%GBPHKD+0.32%CADJPY+0.31%AUDSGD+0.31%GBPUSD+0.30%NZDSGD+0.30%GBPMXN-0.28%USDTRY+0.27%NZDUSD+0.27%CHFJPY-0.27%AUDUSD+0.26%USDNOK-0.26%EURCHF+0.25%EURGBP-0.23%NZDMXN+0.23%GBPJPY+0.22%USDZAR-0.21%USDCHF+0.20%GBPSGD+0.20%EURAUD-0.18%AUDJPY+0.18%NZDJPY+0.18%NOKJPY+0.17%EURNZD-0.17%EURNOK-0.16%USDILS+0.16%AUDDKK+0.16%CHFNOK-0.16%CHFSGD+0.16%NZDCAD-0.16%USDSEK-0.16%EURSGD+0.15%USDPLN-0.15%SGDJPY-0.14%AUDCAD-0.13%EURZAR-0.12%EURHKD+0.09%USDDKK-0.09%GBPZAR-0.08%GBPCAD-0.08%USDJPY-0.07%PLNJPY+0.07%EURSEK-0.07%EURCNH+0.06%CHFSEK-0.06%EURUSD+0.06%USDSGD+0.06%GBPAUD+0.06%EURPLN-0.06%USDCOP-0.04%GBPNZD+0.03%USDCNH-0.03%USDTHB+0.03%AUDNZD+0.02%USDMXN-0.01%EURJPY-0.01%EURCZK+0.01%USDHKD+0.01%AUDNOK0.00%EURDKK0.00%HG1+0.74%COTTON+0.71%S1+0.47%XNGUSD+0.32%W1-0.28%XAGUSD+0.26%GAGUSD+0.25%UKOIL-0.18%USOIL-0.16%XAUUSD+0.13%GAUUSD+0.13%XPTUSD+0.06%BTCUSD+2.39%ETHUSD+17.67%USDTUSD+0.02%XRPUSD+11.86%SOLUSD+12.05%TRXUSDT+0.77%ZECUSDT+8.57%DOGEUSD+14.12%XMRUSDT+5.80%LINKUSD+13.42%XLMUSD+0.27%BCHUSDT+5.89%UNIUSD+7.49%LTCUSD+9.66%SUIUSD+3.37%HBARUSDT+0.35%TONUSD+26.15%TAOUSDT+3.90%AAVEUSD+3.58%DOTUSDT-0.20%ICPUSDT+0.78%ONDOUSDT+0.36%WLDUSDT-0.02%ARBUSDT+6.66%JUPUSDT+0.62%ATOMUSDT+1.90%INJUSDT+13.30%STXUSDT+6.52%FETUSDT+2.74%TIAUSDT+9.19%PYTHUSDT-0.74%SEIUSDT+4.57%IMXUSDT+0.63%OPUSDT+18.94%GRTUSDT+4.09%IOTAUSDT+0.88%WIFUSDT+2.70%AXSUSDT-1.83%POLUSDT+2.78%FARTCOINUSDT+0.63%EOSUSDT+2.70%DYDXUSDT+3.44%GALAUSDT-1.87%ORDIUSDT-0.09%RONINUSDT-3.42%NOTUSDT+1.21%NVDA+0.21%AAPL-0.23%GOOGL+0.30%MSFT-0.42%AMZN-0.29%TSM+0.17%SPCX-4.21%META+0.03%AVGO+0.73%TSLA-0.15%BRK-B+0.61%SKHY-3.19%LLY-1.36%MU+0.27%AMD+1.90%WMT-0.71%JPM-0.86%V+1.74%XOM+1.12%ASMLa-4.20%JNJ-5.73%MA+1.63%INTC+1.44%0700.HK-0.03%ABBV-2.40%1398.HK-1.41%CSCO-0.23%CVX+1.27%COST-0.50%ORCL+4.23%KO+0.36%BAC-1.14%DELL-0.72%LRCX-2.73%AMAT-6.69%PG-0.10%AP2d-8.45%CAT-3.33%UNH-0.20%3988.HK-1.16%1816.HK-25.11%0005.HK-1.09%HSBA.L+0.17%0857.HK+0.29%GE-0.33%PM-1.34%0939.HK-1.63%1288.HK-2.19%MS-1.78%NFLX-0.21%CADCHF+0.61%GBPCHF+0.52%AUDCHF+0.46%NZDCHF+0.45%GBPTRY+0.41%USDCAD-0.39%EURCAD-0.35%GBPHKD+0.32%CADJPY+0.31%AUDSGD+0.31%GBPUSD+0.30%NZDSGD+0.30%GBPMXN-0.28%USDTRY+0.27%NZDUSD+0.27%CHFJPY-0.27%AUDUSD+0.26%USDNOK-0.26%EURCHF+0.25%EURGBP-0.23%NZDMXN+0.23%GBPJPY+0.22%USDZAR-0.21%USDCHF+0.20%GBPSGD+0.20%EURAUD-0.18%AUDJPY+0.18%NZDJPY+0.18%NOKJPY+0.17%EURNZD-0.17%EURNOK-0.16%USDILS+0.16%AUDDKK+0.16%CHFNOK-0.16%CHFSGD+0.16%NZDCAD-0.16%USDSEK-0.16%EURSGD+0.15%USDPLN-0.15%SGDJPY-0.14%AUDCAD-0.13%EURZAR-0.12%EURHKD+0.09%USDDKK-0.09%GBPZAR-0.08%GBPCAD-0.08%USDJPY-0.07%PLNJPY+0.07%EURSEK-0.07%EURCNH+0.06%CHFSEK-0.06%EURUSD+0.06%USDSGD+0.06%GBPAUD+0.06%EURPLN-0.06%USDCOP-0.04%GBPNZD+0.03%USDCNH-0.03%USDTHB+0.03%AUDNZD+0.02%USDMXN-0.01%EURJPY-0.01%EURCZK+0.01%USDHKD+0.01%AUDNOK0.00%EURDKK0.00%HG1+0.74%COTTON+0.71%S1+0.47%XNGUSD+0.32%W1-0.28%XAGUSD+0.26%GAGUSD+0.25%UKOIL-0.18%USOIL-0.16%XAUUSD+0.13%GAUUSD+0.13%XPTUSD+0.06%BTCUSD+2.39%ETHUSD+17.67%USDTUSD+0.02%XRPUSD+11.86%SOLUSD+12.05%TRXUSDT+0.77%ZECUSDT+8.57%DOGEUSD+14.12%XMRUSDT+5.80%LINKUSD+13.42%XLMUSD+0.27%BCHUSDT+5.89%UNIUSD+7.49%LTCUSD+9.66%SUIUSD+3.37%HBARUSDT+0.35%TONUSD+26.15%TAOUSDT+3.90%AAVEUSD+3.58%DOTUSDT-0.20%ICPUSDT+0.78%ONDOUSDT+0.36%WLDUSDT-0.02%ARBUSDT+6.66%JUPUSDT+0.62%ATOMUSDT+1.90%INJUSDT+13.30%STXUSDT+6.52%FETUSDT+2.74%TIAUSDT+9.19%PYTHUSDT-0.74%SEIUSDT+4.57%IMXUSDT+0.63%OPUSDT+18.94%GRTUSDT+4.09%IOTAUSDT+0.88%WIFUSDT+2.70%AXSUSDT-1.83%POLUSDT+2.78%FARTCOINUSDT+0.63%EOSUSDT+2.70%DYDXUSDT+3.44%GALAUSDT-1.87%ORDIUSDT-0.09%RONINUSDT-3.42%NOTUSDT+1.21%
SB

Standard BioTools Inc. (LAB)

NASDAQ • Healthcare

$0.65
+$0 (+0.2%)
Market closed

Last close at October 13, 2026 at 20:00 UTC

Open$0.66
Day Range$0.65 - $0.67
Avg. Volume (3M)969.7K
Market Cap$257.9M
52 Week Range
$0.63$1.72
Next EarningsIn 20 daysNov 3, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$20.1M100%
Gross Profitminus cost of goods$10.5M52%

Fundamentals & Financials

Revenue (TTM)
$84.5M
Net Income (TTM)
-$87.3M
EPS (TTM)
-$0.23
ROA (TTM)
-13.93%
Current Ratio
9.1

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+300.0%Q1 2026$0.06
0.0%Q2 2026-$0.02
-449.0%Q3 2026-$0.07
Next

Nov 3

in 20 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -449.0%

Standard BioTools’ revenue missed consensus and declined year over year in the second fiscal quarter of 2026, reported August 5, 2026, with revenue of about $20.1 million down ~8% (from $21.8 million a year ago) and trailing the $20.8 million estimate (-3.4%). The company posted EPS of -$0.07 (versus -$0.04 a year ago) and a net loss of roughly $26.8 million, narrowing ~20% from a net loss of about $33.5 million a year earlier. Gross profit came in around $10.5 million, translating to a gross margin of roughly 52%, while operating results remained deeply negative with operating income of about -$25.4 million and an operating margin near -126%. Cash flow from operations was negative at roughly $10.3 million. For the next period, consensus calls for EPS of -$0.02 on revenue of $18.8 million.

Next report — what to expect

Standard BioTools Inc. (LAB) reports next on November 3, 2026. Wall Street is looking for EPS of -$0.02 on revenue of $18.8 million. For trailing context, revenue fell -7.6% year over year last quarter. The company has beaten EPS in 3 of its 8 most recent quarters.

View full earnings history

About Standard BioTools Inc.

Standard BioTools Inc. develops life-science tools for healthcare and research markets, selling on NASDAQ as LAB. The company operates in medical technologies used by clinical, diagnostic, and research customers, and generated $85.3 million of revenue in FY2025. Its portfolio spans instrumentation, consumables, services, and assays, including the Hyperion spatial biology platform.

Name
Standard BioTools Inc.
CEO
Michael Egholm
Industry
Healthcare
Year Founded
1999
Employees
387

Today's Snapshot

AI-generated

The day ended with LAB slightly higher at 0.66, while its sector was weaker. Trading was lighter than usual, with volume about a third of its usual level.

Trading Volume

Below 10d avg (1.1M)

368.7K

vs S&P 500 Today

Moderate Outperformance

+0.19%

Updated: October 13, 2026 at 20:16 UTC

Technical Indicators

1 Buy1 Neutral6 Sell
The tape for LAB shows a clear bearish tilt as the stock trades below most short- and long-term moving averages, including the 200-day, while the classic pivot sits marginally above the current price near $0.67. Momentum indicators are weak overall — RSI is below neutral and CCI is deeply negative — and MACD also signals downside pressure, while volatility is modest but meaningful relative to price with an ATR around $0.04 (about 6%). Volume trends are negative on balance, and trend strength is shallow with ADX in the mid-teens. Technical takeaway: Downside bias remains as price trades below key averages amid weak momentum and low trend strength.
All signals
  • EMA (5 indicators)$0.69 - $0.96
    Sell
  • RSI (14)39.34
    Neutral
  • Stochastic %K (14, 3, 3)18.27
    Buy
  • MACD Level (12, 26)-0.01
    Sell
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.